![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 41, 28916-28921, October 8, 1999
From the Tumor necrosis factor-related apoptosis-inducing
ligand (TRAIL), a new member of the tumor necrosis factor (TNF) family,
induces apoptosis primarily of transformed cells. Interleukin-1 was
previously found to protect the keratinocyte cell line KB from
TRAIL-induced apoptosis, thus we studied whether interleukin-1 also
protects from other apoptotic stimuli (ultraviolet radiation (UV),
CD95-ligand). Interleukin-1 rescued KB cells from TRAIL- and
CD95-induced apoptosis, which was critically dependent on nuclear
factor During apoptosis, a complex death program becomes initiated that
ultimately leads to the fragmentation of the cell. The death program
can be either initiated by the cell itself when the time has come to
die (programmed cell death) or by certain external stimuli activating
death receptors on the cell surface (for review, see Ref. 1). Thus,
apoptosis does not only play an important role in the development and
maintenance of tissue homeostasis but also represents an effective
mechanism by which harmful cells can be eliminated. Induction of
apoptosis allows the organism to get rid of infected cells and also of
tumor cells. Accordingly, resistance to apoptosis was identified as an
important event in tumorigenesis. Apoptosis of tumor cells can be
initiated by triggering cell death receptors, leading to activation of
the intracellular apoptotic machinery (2). Chemotherapeutic drugs used
in cancer treatment may exert their therapeutic effects by activating
these pathways (3-5). On the other hand, it is known that defects in the apoptotic pathways or activation of antiapoptotic machineries can
confer resistance to chemotherapy (for review, see Refs. 6 and 7). In
addition, tumor cells can escape apoptotic elimination by
down-regulation of apoptosis-related molecules on the cell surface (8,
9). Consequently, control of the balance between pro- and antiapoptotic
processes within the cell has been recognized as an important target
for therapeutic intervention. Thus, elucidation of the molecular
mechanisms regulating these processes is of primary interest.
Tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL),1 also called APO-2
ligand, is a recently identified molecule belonging to the tumor
necrosis factor (TNF) family that was characterized by its ability to
induce apoptosis (10, 11). Among the TNF family members, TRAIL displays
highest homology to CD95-ligand (CD95L), which induces apoptosis by
triggering the surface receptor CD95 (Fas/APO-1) (12). In contrast to
CD95L, TRAIL was found to induce apoptosis in numerous transformed cell
lines but to kill normal cells less effectively (10, 11). Because of
the unique ability to induce apoptosis preferentially in cancer but not
in normal cells, TRAIL may be highly efficient in specifically eradicating tumor cells in vivo (13). Thus, TRAIL has
prospects of becoming an effective anticancer drug of the future.
Recently, we observed that preincubation with the pro-inflammatory
cytokine interleukin-1 (IL-1) renders transformed keratinocytes
resistant to the apoptotic effect of TRAIL (14). The protective effect of IL-1 against TRAIL-induced apoptosis seems to be mediated via activation of the transcription factor nuclear factor Therefore, we were interested in expanding these observations by
studying whether the antiapoptotic effect of IL-1 is restricted to
TRAIL or whether other apoptotic stimuli are inhibited as well. Here,
we show that IL-1 protects transformed keratinocytes from TRAIL- and
CD95-mediated apoptosis. In contrast, apoptosis induced by ultraviolet
(UV) irradiation was not only not prevented by IL-1 but was even
further enhanced. This opposite effect of IL-1 was also observed when
studying the expression of the antiapoptotic proteins c-IAP1 and
c-IAP2. Thus, these data suggest that antiapoptotic activity of a
stimulus does not only depend on its nature but also on the stimulus
causing apoptosis.
Cells--
The epitheloid carcinoma cell line KB (American Type
Culture Collection, Manassas, VA) and the spontaneously transformed
human keratinocyte cell line HaCaT (kindly provided by N. Fusenig,
Deutsches Krebsforschungszentrum, Heidelberg, Germany) (17) were
cultured in RPMI containing 10% fetal calf serum and 1% glutamine at
37 °C with 5% CO2 in a humidified atmosphere.
Irradiation of cells with UV light was performed using a bank of 4 FS20
bulbs (Westinghouse Electric Corp., Pittsburgh, PA) which emit most of
their energy within the UVB range (290-320 nm) with an emission peak
at 313 nm as described (18). Subconfluent cells were exposed through PBS to a dose of 300 J/m2, unless otherwise stated.
Reagents--
Recombinant human TRAIL protein was provided from
Immunex Corp., Seattle, WA. This is a leucine zipper form of TRAIL that requires no further cross-linking for induction of maximal
apoptotic acitivity (19). Recombinant CD95L and an agonistic
antibody against CD95 (CD95-Ab) were obtained from Alexis and
Immunotech, respectively. Antibodies directed against caspase-3 and
poly(ADP-ribose) polymerase (PARP) were obtained from Dianova, Hamburg
and Roche Molecular Biochemicals, Mannheim, Germany, respectively.
Antibodies directed against c-IAP1, c-IAP2, and the fluorescein
isothiocyanate-conjugated secondary antibodies were purchased from
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Recombinant human
IL-1 Detection of Cell Death--
For the detection of DNA
fragmentation, a cell death detection enzyme-linked immunosorbent assay
(Roche Molecular Biochemicals) was used. The enrichment of mono- and
oligonucleosomes released into the cytoplasm is calculated using the
formula: absorbance of sample cells/absorbance of control cells.
Enrichment factor was used as a parameter of apoptosis and shown on the
y axis as mean ± S.D. of triplicates.
Quantitation of apoptosis by annexin V binding was performed using a
commercially available kit (Bender Corp., Vienna, Austria). Briefly,
cells were washed and resuspended in annexin V binding buffer.
Fluorescein isothiocyanate-conjugated annexin V was added, and the
samples were analyzed by flow cytometry (Epics XL, Coulter, Miami, FL).
Western Blot Analysis--
Cells were harvested and lysed in
RIPA buffer (10 mM Tris, pH 8, 150 mM NaCl, 1%
Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 1 mM
phenylmethylsulfonyl fluoride, 4 µg/ml aprotinin, 1 mM
sodium orthovanadate) for 15 min on ice. After centrifugation, supernatants were collected, and the protein content measured using a
Bio-Rad Protein Assay kit (Bio-Rad). Protein samples were subjected to
SDS-polyacrylamide gel electrophoresis, blotted onto nitrocellulose
membranes, and incubated with antibodies of interest. To monitor equal
loading, membranes were reprobed with an antibody directed against
Transfection--
Cells (1.5 × 107) were
washed once with PBS and resuspended in 600 µl of PBS, 1.25%
Me2SO. Cells were electroporated with 20 µg of each
plasmid DNA according to the method described by Melkonyan et
al. (21). Transfection efficiency of cells cotransfected with a
plasmid encoding Staining of Intracellular Proteins--
Aliquots of cells
(2 × 105) were harvested 16 h after stimulation,
washed once with PBS, and fixed with 0.8% paraformaldehyde for 5 min
on ice. After washing, cells were treated with 0.3% saponine for 5 min
on ice. Following centrifugation cells were incubated with the
antibodies directed against c-IAP1 or c-IAP2 in 0.3% saponine at
4 °C overnight. Purified goat IgG was used as an isotype control.
None of the stimuli used (TRAIL, CD95-Ab, UV radiation, IL-1) changed
the isotype controls. Cells were washed with PBS and incubated with the
respective fluorescein isothiocyanate-conjugated secondary antibody in
0.3% saponine for 30 min. Cells were washed, resuspended in 0.03%
saponine/PBS, and subsequently analyzed in a flow cytometer.
IL-1 Protects Transformed Keratinocytes from TRAIL- and
CD95-induced Apoptosis but Not from UV-induced Apoptosis--
Because
we had recently observed that IL-1 protects cells from TRAIL-induced
apoptosis (14) we were interested in studying whether this effect is
specific for TRAIL or whether IL-1 also protects cells from other
apoptotic stimuli. Therefore, KB cells were exposed to TRAIL or to an
agonistic CD95-Ab, which induces apoptosis via activation of CD95 (12).
Both TRAIL and CD95-Ab induced apoptotic cell death of KB cells, as
determined by a cell death detection enzyme-linked immunosorbent assay
(Fig. 1). When KB cells were preincubated
with IL-1 for 15 min, cells were almost completely protected from the
apoptotic effect of both TRAIL and the CD95-Ab. Similar data were
obtained with HaCaT cells or when annexin V staining was used as a
read-out system for apoptosis (data not shown). Thus, these data
indicate that IL-1 rescues cells from TRAIL-mediated as well as from
CD95-mediated apoptosis. Similar observations were obtained when
instead of the CD95-Ab recombinant CD95L was used as the apoptotic
stimulus (data not shown).
We next investigated whether IL-1 also protects KB cells from
UV-mediated apoptosis. Therefore, KB cells were exposed to 300 J/m2 in the absence or presence of IL-1 and apoptosis
determined 16 h later. In contrast to CD95- and TRAIL-mediated
apoptosis, prestimulation of KB cells with IL-1 did not protect cells
from UV-induced apoptosis and even caused pronounced enhancement of
cell death (Fig. 1). To exclude that the failure of IL-1 to rescue
cells from UV-induced apoptosis is simply due to the fact that the dose
of 300 J/m2 represents a too severe insult to the cells,
lower UV doses were tested. As shown in Fig.
2, UV irradiation induced apoptosis in a
dose-dependent manner, and in all cases IL-1 enhanced the
apoptotic response.
Caspase-3 is a member of the family of interleukin-1
Caspase-3 cleaves the death substrate PARP (27). Accordingly, PARP was
cleaved from its intact 116-kDa form into the inactive 85-kDa fragment
in samples of TRAIL-, CD95-Ab-, and UV-exposed KB cells (Fig. 3). IL-1
pretreatment significantly reduced TRAIL- and CD95-Ab-induced PARP
cleavage, whereas UV-mediated cleavage of PARP was again enhanced in
the presence of IL-1. Taken together, these data clearly demonstrate
that IL-1 rescues cells from CD95- and TRAIL-induced apoptosis, whereas
UV-induced apoptosis is even enhanced by IL-1.
The Protective Effect of IL-1 Is Critically Dependent on
NF Differential Regulation of Antiapoptotic Proteins by
IL-1--
Because IL-1 protected KB cells from CD95- and TRAIL-induced
apoptosis but enhanced UV-mediated cell death, we were interested in
elucidating the mechanism underlying this heterogenous effect. It has
recently been reported that NF Enhancement of UV-induced Apoptosis by IL-1 Is Due to Endogenous
Release of TNF Recently, IL-1 was shown to protect tumor cells from the apoptotic
effect of TRAIL (14). Because IL-1 can be released by a variety of
tumor cells (15) and is also released by inflammatory cells
participating in the tumor-host immune response (16), cancer cells
under these conditions may escape the possible therapeutic effect of
TRAIL. In this study, we demonstrate that IL-1 does not only protect
transformed cells from TRAIL- but also from CD95-mediated apoptosis.
This effect of IL-1 is clearly due to activation of NF Because NF Recently it was reported that CD95 is critically involved in
UV-mediated apoptosis (24, 39, 40). UV radiation can directly activate
the death receptor by inducing functional aggregation of CD95 (24, 39).
Inhibition of CD95 clustering following UV exposure reduces but does
not completely block apoptosis (24), implying that besides the CD95
pathway other mechanisms must be involved as well. This assumption is
supported by the present findings: if UV-induced apoptosis was to be
exclusively mediated by CD95, both CD95- and UV-induced apoptosis would
be inhibitable by the same interventions. In this case, IL-1 should
have protected KB and HaCaT cells not only from CD95- but also from
UV-induced apoptosis.
According to recent reports (30, 33, 41, 42), NF The apoptotic effects of TNF Taken together, the present study demonstrates that IL-1 can exert
diverse effects on apoptosis. TRAIL- and CD95-mediated apoptosis is
significantly reduced by IL-1 via activation of NF We thank J. Bückmann and P. Wissel for
preparing the graphs and A. Mehling for critically reading the
mansucript. We are grateful to Dr. N. Fusenig for providing HaCaT cells.
*
This work was supported by grants from
Interdisziplinäres Zentrum für Klinische Forschung
Münster (IZKF/D12), the German Research Foundation (Schw
625/1-3), and the European Community (ENV4-CT97-0556). This work is
part of the PhD thesis of G. K.-W.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
To whom correspondence should be addressed: Dept. of
Dermatology, University Münster, Von-Esmarchstrasse 56, D-48149
Münster, Germany. Tel.: 49-251-83-56565; Fax: 49-251-83-58579;
E-mail: schwtho@uni-muenster.de.
The abbreviations used are:
TRAIL, tumor
necrosis factor-related apoptosis-inducing ligand;
CD95-Ab, agonistic
anti-CD95-antibody;
CD95L, CD95 ligand;
IAP, inhibitor of apoptosis
protein;
IL-1, interleukin-1;
NF
Interleukin-1 Protects Transformed Keratinocytes from Tumor
Necrosis Factor-related Apoptosis-inducing Ligand- and CD95-induced
Apoptosis but Not from Ultraviolet Radiation-induced Apoptosis*
,
,
,
¶
Ludwig Boltzmann Institute for Cell Biology
and Immunobiology of the Skin, Department of Dermatology, University of
Münster, Von-Esmarchstrasse 56, D-48149 Münster, Germany
and § Immunex Corporation, Seattle, Washington 98101
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
B, because cells transfected with a super-repressor form of
the nuclear factor
B inhibitor I
B were less protected. In
contrast, UV-mediated apoptosis was not only not prevented by
interleukin-1 but even enhanced. This opposite effect of interleukin-1
was also observed for the expression of the inhibitor of apoptosis
proteins (IAP). Whereas TRAIL- and CD95-mediated suppression of IAP
expression was partially reversed by interleukin-1, UV-mediated
down-regulation of IAPs was not reversed but even further enhanced.
Increased apoptosis induced by interleukin-1 plus UV was accompanied by excessive TNF
release, implying that enhanced cytotoxicity is due to
the additive effect of these two apoptotic stimuli. Accordingly, enhanced apoptosis was reduced by blocking the TNF receptor-1. The
opposite effects of interleukin-1 indicate that different mechanisms
are involved in UV-induced apoptosis compared with CD95- and
TRAIL-mediated apoptosis. Furthermore, the data suggest that whether a
signal acts in an antiapoptotic way or not does not only depend on the
signal itself but also on the stimulus causing apoptosis.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
B (NF
B). The observation that transformed cells become resistant to TRAIL upon
exposure to IL-1 was the first demonstration of a pathway that allows
tumor cells to escape the killing effect of TRAIL. Because IL-1 is
secreted by a variety of tumor cells (15) and is also released by
inflammatory cells participating in the tumor-host immune response
(16), tumors under these conditions could become resistant to TRAIL
in vivo.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
was obtained from Roche Molecular Biochemicals. TNF
was
measured by use of an ultrasensitive TNF
enzyme-linked immunosorbent
assay (Diaclone, Besancon, France). Plasmids allowing overexpression of
a mutated I
B variant were kindly provided by K. Schulze-Osthoff,
Münster, Germany (20).
-tubulin (Pharmingen, San Diego, CA). Signals were detected with an
ECL kit (Amersham Pharmacia Biotech, Buckinghamshire, UK).
-galactosidase (pcDNA6/VS-His/lacZ; Invitrogen, San Diego, CA) was determined 24 h later by staining with X-gal (100 µg/ml) in 5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, and 1 mM
MgCl2 in PBS.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (12K):
[in a new window]
Fig. 1.
IL-1 protects from TRAIL- and CD95-induced
apoptosis but not from UV-induced apoptosis. KB cells were exposed
to TRAIL (32 ng/ml), CD95-Ab (1 µg/ml), or UV light (300 J/m2) in the absence or presence of recombinant human
IL-1
(10 ng/ml). Control cells (Co) were left untreated.
Apoptosis was examined 16 h later by determining nucleosomal DNA
fragmentation using an apoptosis determination kit. The rate of
apoptosis is reflected by the enrichment of nucleosomes in the
cytoplasm shown by the values on the y axis. Data presented
show the representative results of one of three independently performed
experiments.

View larger version (19K):
[in a new window]
Fig. 2.
IL-1 enhances UV-induced apoptosis
independently of the UV dose. KB cells were exposed to various
doses of UV radiation (100, 200, or 300 J/m2) in the
absence or presence of IL-1
(10 ng/ml). Cells were stained 16 h
later with fluorescein isothiocyanate-conjugated annexin V and
subjected to flow cytometry analysis. Histograms show fluorescence
intensity (x axis) versus cell number
(y axis).
converting
enzyme proteases that is involved in CD95-, TRAIL-, and UV-mediated cell killing (22-25). For activation, caspase-3 must be cleaved from
its 32-kDa proform into its 17-kDa active form (26). Thus, caspase-3
cleavage can serve as an additional read-out system to evaluate
apoptosis. Therefore, KB cells were exposed to TRAIL, CD95-Ab, or to UV
light either in the absence or presence of IL-1. Cell lysates were
prepared 16 h later for Western blot analysis using an antibody
against caspase-3. Because this antibody is directed against the
caspase-3 proform, it cannot recognize the processed 17-kDa form, and a
loss of the immunoreactive band in samples in which caspase-3 is
activated can be observed. Significant reduction of the caspase-3
proform was observed in protein extracts of KB cells that were treated
either with TRAIL, CD95-Ab, or UV light (Fig.
3). Preincubation of cells with IL-1
almost completely prevented TRAIL- and CD95-induced caspase-3
activation. In contrast, IL-1 enhanced UV-induced caspase-3 activation,
which is shown by the complete disappearance of the immunoreactive
band.

View larger version (27K):
[in a new window]
Fig. 3.
IL-1 differentially affects cleavage of
caspase-3 and PARP. KB cells were exposed to TRAIL (32 ng/ml)
(lanes 2 and 3), CD95-Ab (1 µg/ml) (lanes
4 and 5), or UV radiation (300 J/m2)
(lanes 6 and 7) in the absence (lanes
1, 2, 4, and 6) or presence
(lane 3, 5, and 7) of 10 ng/ml
IL-1
. Control cells were left untreated (lane 1).
Proteins were extracted 16 h after treatment, and Western blot
analysis was performed using antibodies directed against caspase-3,
PARP, or
-tubulin.
B--
We recently proposed that IL-1 might rescue cells from
TRAIL-induced apoptosis via activation of NF
B, because IL-1
activated NF
B in KB cells. Furthermore, inhibition of NF
B
activation by the proteasome inhibitor MG132 antagonized the protective
effect of IL-1 (14). Activation of NF
B is associated with
degradation of the inhibitory protein I
B by the proteasome pathway.
Upon triggering of the IL-1 receptor, I
B becomes phosphorylated at the serine residues 32 and 36, which acts as a signal for ubiquination and subsequent degradation of I
B by the 26 S proteasome (28, 29).
Thus, I
B degradation and consequently NF
B activation can be
blocked by proteasome inhibitors such as MG132 or lactacystin (29).
However, the approach using proteasome inhibitors provides only
indirect evidence that the protective effect of IL-1 is due to
activation of NF
B, because one cannot exclude that the inhibitors like MG132 may affect other pathways as well. Thus, we addressed whether IL-1 protects KB cells from TRAIL- and CD95-mediated apoptosis via activation of NF
B by overexpressing a super-repressor form of
I
B. In this mutant form, two point mutations (Ser-32
Ala, Ser-36
Ala) prevent phosphorylation and subsequent proteasomal degradation
of I
B (20). As a consequence, NF
B release, nuclear translocation,
and functional DNA binding is prevented. Whereas KB cells transfected
with the empty cytomegalovirus vector were still rescued by IL-1, the
protective effect of IL-1 on TRAIL- and CD95-induced apoptosis was
significantly reduced in cells transfected with the I
B
super-repressor (Fig. 4). These results support the concept that IL-1-mediated protection from TRAIL- and
CD95-induced apoptosis is dependent on NF
B activation.

View larger version (38K):
[in a new window]
Fig. 4.
IL-1 protects from TRAIL- and CD95-induced
apoptosis via activation of NF
B. KB cells
were transiently transfected with a plasmid allowing overexpression of
the super-repressor form of the NF
B inhibitor I
B (pRc I
B
D/N) or with the empty control vector (pRc CMV) only.
Cells were stimulated with TRAIL (32 ng/ml) or CD95-Ab (0.4 µg/ml) in
the absence or presence of IL-1
(10 ng/ml) 30 h after
transfection. Control cells (Co) were left untreated.
Apoptosis was examined 16 h after treatment by determining
nucleosomal DNA fragmentation using an apoptosis determination kit. The
rate of apoptosis is reflected by the enrichment of nucleosomes in the
cytoplasm shown by the values on the y axis. Data presented
show the representative results of one of three independently performed
experiments.
B may exert its antiapoptotic effect
via induction of several proteins including the inhibitor of apoptosis
proteins (IAP) c-IAP1 and c-IAP2 (30). Therefore we investigated how
IL-1 affects c-IAP1 and c-IAP2 expression in KB cells exposed to the
different apoptotic stimuli. Intracellular protein expression evaluated
by fluorescence-activated cell sorter analysis revealed that KB cells
express c-IAP1 and c-IAP2 constitutively (Fig.
5). Exposure of KB cells to either TRAIL,
CD95-Ab, or UV light caused a down-regulation of both c-IAP proteins.
IL-1 alone only marginally enhanced constitutive c-IAP1 and c-IAP2
expression (data not shown), but reversed CD95- and TRAIL-induced
down-regulation of c-IAP1 and c-IAP2 partially (Fig. 5). The opposite
effect was exerted by IL-1 when cells were exposed to UV light. In this
case, IL-1 did not reverse reduced c-IAP1 and c-IAP2 protein levels, but even slightly further enhanced the down-regulation. Taken together,
IL-1 appears to affect c-IAP levels differentially depending on the
stimulus that induces apoptosis. The further reduction of c-IAP
expression in UV-exposed cells by IL-1 might be an explanation why IL-1
enhances UV-induced apoptosis.

View larger version (27K):
[in a new window]
Fig. 5.
IL-1 differentially affects expression
of c-IAP1 and c-IAP2. KB cells were treated with TRAIL (32 ng/ml), CD95-Ab (1 µg/ml), or UV light (300 J/m2) in the
absence or presence of IL-1
(10 ng/ml). Control cells
(Co) were left untreated. Cells were fixed 16 h later,
permeabilized, and incubated with antibodies against c-IAP1 or c-IAP2.
After incubation with fluorescein isothiocyanate-conjugated secondary
antibodies, cells were subjected to flow cytometry. Purified IgG was
used as an isotype control. Histograms show fluorescence intensity
(x axis) versus cell number (y axis).
Mean fluorescence intensity (MFI) is indicated in each
graph. Data presented show representative results of one of three
independently performed experiments.
--
TNF
can generate two types of signals, one
that induces apoptosis (31) and one that activates NF
B (32). The
overall result in a specific cell type under specific conditions
appears to be dependent on the balance of the two signals (32). When KB
cells were treated with TNF
in addition to TRAIL, an enhancement of
apoptosis was observed (data not shown), indicating that under these
conditions the death signal caused by TNF
overrules activation of
NF
B. Consequently, both stimuli induce apoptosis in an additive way.
Because TNF
can be released by KB cells (18) we looked into whether
the enhancing effect of IL-1 on UV-induced apoptosis might be due
to autocrine release of TNF
. To address this issue, KB and HaCaT
cells, respectively, were exposed to TRAIL, CD95-Ab, or UV radiation in
the absence or presence of IL-1. KB and HaCaT cells did not
constitutively release TNF
. IL-1, TRAIL, or CD95-Ab alone or in any
combination induced TNF
secretion only marginally. whereas UV
irradiation induced moderate release of TNF
. In contrast, when cells
were stimulated with UV light plus IL-1, dramatically enhanced TNF
release was observed (Table I). To
substantiate that TNF
released under these conditions is involved in
the enhanced induction of apoptosis, an antibody neutralizing the TNF
receptor type 1 which mediates apoptosis (34) was used. Preincubation with the antibody caused a complete loss of the enhancing effect of
IL-1 on UV-induced apoptosis (Fig. 6).
This indicates that increased apoptosis of UV-exposed KB and
HaCaT cells in the presence of IL-1 is due to the autocrine
release of TNF
, which then enhances apoptosis.
Exposure of keratinocytes to IL-1 and UV radiation results in excessive
release of TNF
levels
were measured with an enzyme-linked immunosorbent assay.

View larger version (15K):
[in a new window]
Fig. 6.
Enhancement of UV-induced apoptosis by IL-1
is inhibited by blocking the TNF receptor type 1. KB and HaCaT
cells, respectively, were exposed to UV radiation (300 J/m2) in the absence or presence of IL-1
(10 ng/ml). An
antibody blocking the TNF receptor type 1 was added (500 ng/ml).
Apoptosis was examined 16 h after treatment by determining
nucleosomal DNA fragmentation using an apoptosis determination kit. The
rate of apoptosis is reflected by the enrichment of nucleosomes in the
cytoplasm shown by the values on the y axis. Data presented
show the representative results of one of three independently performed
experiments.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
B, because
inhibition of NF
B by overexpression of a dominant negative mutant of
I
B prevented protection by IL-1. Protection from CD95-induced
apoptosis by IL-1 might also affect the activity of those
chemotherapeutic drugs that exert their cytotoxic effect via the
CD95/CD95L system (3-5). This assumption is also supported by the
observation that activation of NF
B protects cells against apoptosis induced by the cytostatic drug daunorubicin (35).
B rescues cells from death induced by TNF
(35-38),
TRAIL (13), ionizing radiation (35), chemotherapeutic drugs (35), and,
as demonstrated in this study, from CD95-mediated cell death, NF
B
appears to protect from apoptosis in general. Thus, it was quite
surprising to observe that IL-1 did not protect but even enhanced
apoptosis induced by UV radiation.
B appears to exert
its antiapoptotic effects via the induction of antiapoptotic proteins,
including c-IAP1, c-IAP2, X-linked IAP, and IEX-1L. Therefore, we were
interested in the effect IL-1 may exert on the expression of IAPs in
cells exposed either to TRAIL, CD95-Ab, or UV light. Intracellular
protein measurements revealed that all three apoptotic stimuli reduced
levels of c-IAP1 and c-IAP2, although at different levels. c-IAP1 and
c-IAP2 appear to exert their antiapoptotic activity by specifically
binding to the terminal effector domains of caspase-3 and -7 (43). In contrast to the mode of action of these proteins, little is known about
how c-IAPs are regulated, except that they are under control of NF
B
and that c-IAP2 can exert a positive feedback control on NF
B via an
I
B targeting mechanism (44). This study for the first time
demonstrates negative regulation of c-IAP expression by apoptotic
stimuli. Because this was assessed only by determining the protein
expression, we do not as yet know whether this inhibition is
transcriptionally regulated. Although the mechanisms by which c-IAPs
are down-regulated remain to be determined, this phenomenon might be of
relevance for the execution of apoptosis. CD95- and TRAIL-mediated
down-regulation of both c-IAP1 and c-IAP2 was partially antagonized by
IL-1. Thus, induction of c-IAP1 and c-IAP2 might be the mechanism by
which IL-1 rescues cells from CD95- and TRAIL-induced apoptosis. In
contrast, UV-mediated down-regulation of c-IAPs was not restored by
IL-1 but even further enhanced slightly. Although we do not yet know
the mechanism by which IL-1 affects c-IAP expression in such a
different way, the present data indicate that whether a signal acts in
an antiapoptotic way or not does not only depend on the signal itself
but also on the stimulus causing apoptosis.
on most cells can only be observed when
protein synthesis is blocked, suggesting that de novo protein synthesis protects cells by induction of antiapoptotic genes (35). Keratinocytes are able to release TNF
(18), and we
therefore hypothesized that enhancement of UV-induced apoptosis by IL-1
may be mediated by the autocrine release of TNF
. Because protective
c-IAPs are down-regulated upon UV-exposure, under these conditions the
apoptotic effect of TNF
could dominate the activation of NF
B.
Indeed, the enhancing effect of IL-1 on UV-induced apoptosis was
completely reversed when the experiment was performed in the presence
of an antibody, which blocks the TNF-receptor type 1. Accordingly,
excessively enhanced levels of TNF
were detected when cells were
exposed to UV radiation in the presence of IL-1. Neither TRAIL nor
CD95-Ab synergized with IL-1 to induce TNF
release from KB or HaCaT
cells. Thus, this observation is compatible with our hypothesis that
down-regulation of c-IAPs preconditions the cells for the killing
effect of TNF
.
B, whereas
UV-mediated apoptosis is remarkably enhanced via the autocrine release
of TNF
. Thus, IL-1 cannot be regarded as an antiapoptotic cytokine
in general. Furthermore, these findings suggest that whether a stimulus
affects apoptosis in a positive or negative way does not exclusively
depend on the nature of the stimulus itself but also on the signal that
induces apoptosis. As demonstrated here, completely opposite effects
can be obtained in different apoptosis systems.
![]()
ACKNOWLEDGEMENT
![]()
FOOTNOTES
![]()
ABBREVIATIONS
B, nuclear factor-
B;
PARP, poly(ADP-ribose) polymerase;
TNF, tumor necrosis factor;
PBS, phosphate-buffered saline.
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Cohen, J. J.
(1993)
Immunol. Today
14,
126-130[Medline]
[Order article via Infotrieve]
2.
Korsmeyer, S. J.,
and Greenberg, P. D.
(1998)
Curr. Opin. Immunol.
10,
543-544[CrossRef]
3.
Friesen, X.,
Herr, I.,
Krammer, P. H.,
and Debatin, K. M.
(1996)
Nat. Med.
2,
574-577[CrossRef][Medline]
[Order article via Infotrieve]
4.
Müller, M.,
Strand, S.,
Hug, H.,
Heinermann, E. M.,
Walczak, H.,
Hofmann, W. J.,
Stremmel, W.,
Krammer, P. H.,
and Galle, P. R.
(1997)
J. Clin. Invest.
99,
403-413[Medline]
[Order article via Infotrieve]
5.
Gamen, S.,
Anel, A.,
Lasierra, P.,
Alava, M. A.,
Martrinex-Lorenzo, M. J.,
Pineiro, A.,
and Naval, J.
(1997)
FEBS Lett.
417,
360-364[CrossRef][Medline]
[Order article via Infotrieve]
6.
Haq, R.,
and Zanke, B.
(1998)
Cancer Metastasis Rev.
17,
233-239[CrossRef][Medline]
[Order article via Infotrieve]
7.
Bold, R. J.,
Termuhlen, P. M.,
and McConkey, D. J.
(1997)
Surg Oncol.
6,
133-142[CrossRef][Medline]
[Order article via Infotrieve]
8.
Hughes, S. J.,
Nambu, Y.,
Soldes, O. S.,
Hamstra, D.,
Rehemtulla, A.,
Iannettoni, M. D.,
Orringer, M. B.,
and Beer, D. G.
(1997)
Cancer Res.
75,
5571-5578
9.
Nambu, Y.,
Hughes, S. J.,
Rehemtulla, A.,
Hamstra, D.,
Orringer, M. B.,
and Beer, D. G.
(1998)
J. Clin. Invest.
101,
1102-1110[Medline]
[Order article via Infotrieve]
10.
Wiley, S. R.,
Schooley, K.,
Smolak, P. J.,
Din, W. S.,
Huang, C. P.,
Nicholl, J. K.,
Sutherland, G. R.,
Smith, T. D.,
Rauch, C.,
Smith, C. A.,
and Goodwin, R. G.
(1995)
Immunity
3,
673-682[CrossRef][Medline]
[Order article via Infotrieve]
11.
Pitti, R. M.,
Marsters, S. C.,
Ruppert, S.,
Donahue, C. J.,
Moore, A.,
and Ashkenazi, A.
(1996)
J. Biol. Chem.
271,
12687-12690 12.
Peter, M. E.,
and Krammer, P. H.
(1998)
Curr. Opin. Immunol.
10,
545-551[CrossRef][Medline]
[Order article via Infotrieve]
13.
Walczak, H.,
Miller, R. E.,
Ariail, K.,
Gliniak, B.,
Griffith, T. S.,
Kubin, M.,
Chin, W.,
Jones, J.,
Woodward, A.,
Le, T.,
et al..
(1999)
Nat. Med.
5,
157163
14.
Kothny-Wilkes, G.,
Kulms, D.,
Pöppelmann, B.,
Luger, T. A.,
Kubin, M.,
and Schwarz, T
(1998)
J. Biol. Chem.
273,
29247-29253 15.
Luger, T. A.,
and Schwarz, T.
(1992)
in
Pharmacology of the Skin
(Mukhtar, H., ed)
, pp. 283-313, CRC Press, Boca Raton, FL
16.
Durum, S. K.,
Oppenheim, J. J.,
and Neta, R.
(1990)
in
Immunophysiology. The Role of Cells and Cytokines in Immunity and Inflammation
(Oppenheim, J. J.
, and Shevach, E. M., eds)
, pp. 210-225, Oxford University Press, New York, Oxford
17.
Boukamp, P.,
Petrussevska, R. T,
Breikreutz, D.,
Hornung, J.,
Markham, A.,
and Fusenig, N. E.
(1988)
J. Cell Biol.
106,
761-771 18.
Köck, A.,
Schwarz, T.,
Kirnbauer, R.,
Urbanski, A.,
Perry, P.,
Ansel, J. C.,
and Luger, T. A.
(1990)
J. Exp. Med.
172,
1609-1614 19.
Walczak, H.,
Degli-Esposti, M. A.,
Johnson, R. S.,
Smolak, P. J.,
Waugh, J. Y.,
Boiani, N.,
Timour, M. S.,
Gerhart, M. J.,
Schooley, K. A.,
Smith, C. A.,
Goodwin, R. G.,
and Rauch, C. T.
(1997)
EMBO J.
16,
5386-5397[CrossRef][Medline]
[Order article via Infotrieve]
20.
Traenckner, E. B.-M.,
Wilk, S.,
and Baeuerle, P. A.
(1995)
EMBO J.
14,
2876-2838[Medline]
[Order article via Infotrieve]
21.
Melkonyan, H.,
Sorg, C.,
and Klempt, M.
(1996)
Nucleic Acids Res.
24,
4356-4357 22.
Enari, M.,
Hug, H.,
and Nagata, S.
(1995)
Nature
375,
78-81[CrossRef][Medline]
[Order article via Infotrieve]
23.
Schlegel, J.,
Peter, I.,
Orrenius, S.,
Miller, D. K.,
Thornberry, N. A.,
Yamin, T. T.,
and Nicholson, D. W.
(1996)
J. Biol. Chem.
271,
1841-1844 24.
Aragane, Y.,
Kulms, D.,
Metze, D.,
Kothny, G.,
Pöppelmann, B.,
Luger, T. A.,
and Schwarz, T.
(1998)
J. Cell Biol.
140,
171-182 25.
Mariani, S. M.,
Matiba, B.,
Armandola, E. A.,
and Krammer, P. H.
(1997)
J. Cell Biol.
137,
221-229 26.
Nicholson, D. W.,
Ali, A.,
Thornberry, N. A.,
Vaillancourt, J. P.,
Ding, C. K.,
Gallant, M.,
Gareau, Y.,
Griffin, P. R.,
Labelle, M.,
Lazebnik, Y. A.,
et al..
(1995)
Nature
376,
37-43[CrossRef][Medline]
[Order article via Infotrieve]
27.
Lazebnik, Y. A.,
Kaufmann, S. H.,
Desnoyer, S.,
Poirier, G. G.,
and Earnshaw, W. C.
(1994)
Nature
371,
346-347[CrossRef][Medline]
[Order article via Infotrieve]
28.
Palombella, V. J.,
Rando, O. J.,
Goldberg, A. L.,
and Maniatis, T.
(1994)
Cell
78,
773-785[CrossRef][Medline]
[Order article via Infotrieve]
29.
Traenckner, E. B.-M.,
Wilk, S.,
and Baeuerle, P. A.
(1994)
EMBO J.
13,
5433-544129[Medline]
[Order article via Infotrieve]
30.
Wang, C. Y.,
Mayo, M. W.,
Korneluk, R. G.,
Goeddel, D. V.,
and Baldwin, A. S., Jr.
(1998)
Science
281,
1680-1683 31.
Hale, A. J.,
Smith, C. A.,
Sutherland, L. C.,
Stoenman, V. E. A.,
Longthorne, V. L.,
Culhane, A. C.,
and Williams, G. T.
(1996)
Eur. J. Biochem.
236,
1-26[Medline]
[Order article via Infotrieve]
32.
Barinaga, M.
(1996)
Science
273,
735-737 33.
Stehlik, C.,
de Martin, R.,
Kumabashiri, I.,
Schmid, J. A.,
Binder, B. R.,
and Lipp, J.
(1998)
J. Exp. Med.
188,
211-216 34.
Haridas, V.,
Drany, B. G.,
Natarajan, K.,
Heller, R.,
and Aggarwal, B. B.
(1998)
J. Immunol
160,
3152-3162 35.
Wang, C.-Y.,
Mayo, M. W.,
and Baldwin, A. S., Jr.
(1996)
Science
274,
784-787 36.
Beg, A. A.,
and Baltimore, D.
(1996)
Science
274,
782-784 37.
Liu, Z. G.,
Hsu, H.,
Goeddel, D. V.,
and Karin, M.
(1996)
Cell
87,
565-576[CrossRef][Medline]
[Order article via Infotrieve]
38.
Van Antwerp, D. J.,
Martin, S. J.,
Kafri, T.,
Green, D. R.,
and Verma, I. M.
(1996)
Science
274,
787-789 39.
Rehemtulla, A.,
Hamilton, C. A.,
Chinnaiyan, A. M.,
and Dixit, V. M.
(1997)
J. Biol. Chem.
272,
25783-25786 40.
Leverkus, M.,
Yaar, M.,
and Gilchrest, B. A.
(1997)
Exp. Cell Res.
232,
255-262[CrossRef][Medline]
[Order article via Infotrieve]
41.
Deveraux, Q. L.,
Takahashi, R.,
Salvesen, G. S.,
and Reed, J. C.
(1997)
Nature
388,
300-304[CrossRef][Medline]
[Order article via Infotrieve]
42.
Wu, M. X.,
Ao, Z.,
Prasad, K. V. S.,
Wu, R.,
and Schlossman, S. F.
(1998)
Science
281,
998-1001 43.
Roy, N.,
Deveraux, Q. L.,
Takahashi, R.,
Salvesen, G. S.,
and Reed, J. C.
(1997)
EMBO J.
16,
6914-6925[CrossRef][Medline]
[Order article via Infotrieve]
44.
Chu, Z. L.,
McKinsey, T. A.,
Liu, L.,
Gentry, J. J.,
Malim, M. H.,
and Ballard, D. W.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
10057-10062
Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
L. M. Sedger, S. R. Osvath, X.-M. Xu, G. Li, F. K.-M. Chan, J. W. Barrett, and G. McFadden Poxvirus Tumor Necrosis Factor Receptor (TNFR)-Like T2 Proteins Contain a Conserved Preligand Assembly Domain That Inhibits Cellular TNFR1-Induced Cell Death. J. Virol., September 1, 2006; 80(18): 9300 - 9309. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Maeda, S. W. Schneider, M. Kojima, S. Beissert, T. Schwarz, and A. Schwarz Enhanced photocarcinogenesis in interleukin-12-deficient mice. Cancer Res., March 15, 2006; 66(6): 2962 - 2969. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Schwarz, A. Maeda, S. Stander, H. van Steeg, and T. Schwarz IL-18 reduces ultraviolet radiation-induced DNA damage and thereby affects photoimmunosuppression. J. Immunol., March 1, 2006; 176(5): 2896 - 2901. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Maggio-Price, H. Bielefeldt-Ohmann, P. Treuting, B. M. Iritani, W. Zeng, A. Nicks, M. Tsang, D. Shows, P. Morrissey, and J. L. Viney Dual Infection with Helicobacter bilis and Helicobacter hepaticus in P-Glycoprotein-Deficient mdr1a-/- Mice Results in Colitis that Progresses to Dysplasia Am. J. Pathol., June 1, 2005; 166(6): 1793 - 1806. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Poppelmann, K. Klimmek, E. Strozyk, R. Voss, T. Schwarz, and D. Kulms NF{kappa}B-dependent Down-regulation of Tumor Necrosis Factor Receptor-associated Proteins Contributes to Interleukin-1-mediated Enhancement of Ultraviolet B-induced Apoptosis J. Biol. Chem., April 22, 2005; 280(16): 15635 - 15643. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. D'Errico, M. Teson, A. Calcagnile, T. Nardo, N. De Luca, C. Lazzari, S. Soddu, G. Zambruno, M. Stefanini, and E. Dogliotti Differential Role of Transcription-Coupled Repair in UVB-Induced Response of Human Fibroblasts and Keratinocytes Cancer Res., January 15, 2005; 65(2): 432 - 438. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. D. Southall, J. S. Isenberg, H. Nakshatri, Q. Yi, Y. Pei, D. F. Spandau, and J. B. Travers The Platelet-activating Factor Receptor Protects Epidermal Cells from Tumor Necrosis Factor (TNF) alpha and TNF-related Apoptosis-inducing Ligand-induced Apoptosis through an NF-kappa B-dependent Process J. Biol. Chem., November 30, 2001; 276(49): 45548 - 45554. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. D. S. Jean, C. Debbasch, M. Rahmani, F. Brignole, G. Feldmann, J.-M. Warnet, and C. Baudouin Fas- and Interferon {gamma}-Induced Apoptosis in Chang Conjunctival Cells: Further Investigations Invest. Ophthalmol. Vis. Sci., August 1, 2000; 41(9): 2531 - 2543. [Abstract] [Full Text] |
||||
![]() |
D. Bernard, B. Quatannens, B. Vandenbunder, and C. Abbadie Rel/NF-kappa B Transcription Factors Protect against Tumor Necrosis Factor (TNF)-related Apoptosis-inducing Ligand (TRAIL)-induced Apoptosis by Up-regulating the TRAIL Decoy Receptor DcR1 J. Biol. Chem., July 13, 2001; 276(29): 27322 - 27328. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Kulms, B. Poppelmann, and T. Schwarz Ultraviolet Radiation-induced Interleukin 6 Release in HeLa Cells Is Mediated via Membrane Events in a DNA Damage-independent Way J. Biol. Chem., May 12, 2000; 275(20): 15060 - 15066. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||